Drug firm Mankind Pharma today said it has received licence from the Defence Research and Development Organisation (DRDO) to manufacture and market oral 2-deoxy-D-glucose (2-DG), used for the treatment of COVID-19.
2-DG was developed by the Defence Research and Development Establishment (DRDE), Gwalior. The clinical trials were conducted by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in association with Dr Reddy's Laboratories, Mankind Pharma said in a statement.
The company will manufacture the product at its facilities in Visakhapatnam and Himachal Pradesh, it added.
The office of the Drugs Controller General of India (DCGI) on May 1 had permitted the emergency use of 2-DG as an adjunct treatment for moderate to severe COVID-19 patients, Mankind Pharma said.
The drug is found to help the hospitalised COVID-19 patients recover faster and is also known to reduce the supplemental oxygen dependency among the COVID-19 patients, it added.
"Our objective behind this agreement is to ensure maximum reach of this medication to the deserving Indian patients suffering from the deadly pandemic," the company said.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Video: India Test Fires "Historic" Long-Range Hypersonic Missile India Successfully Conducts Flight Test Of Long Range Land Cruise Missile DRDO Invites Applications For Various Positions, Salary Up To Rs 1.25 Lakh Per Month "Intention To Dupe UPSC": Ex-IAS Trainee Puja Khedkar Denied Pre-Arrest Bail Bangladeshi Traders "Forced" To Import From Pakistan Amid Growing Ties "Congress Should Be Ready...": Mani Shankar Aiyar's Big INDIA Bloc Remark Send Sheikh Hasina Back To Dhaka, Bangladesh Writes To India He Slit Throats Of His 2 Stepbrothers While Dropping Them To School In Assam Texas Congresswoman 'Missing' For 6 Months Found In Dementia Care Home Track Latest News Live on NDTV.com and get news updates from India and around the world.